{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-022428","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.550652+00:00","generated_at":"2026-06-17T18:12:44.179069+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Relmada Q4 net loss $37.9M; cash at $148.3M; plans revised REL-1017 MDD trials after Study 301 failure","bullets":["Q4 2022 net loss $37.9M ($1.28/diluted share), vs $34.4M ($1.80) in Q4 2021; full-year net loss $157.0M.","Cash and short-term investments $148.3M at Dec 31, 2022, down from $211.9M a year earlier.","Will amend ongoing Phase 3 Study 302 and initiate new Study 304 for REL-1017 as adjunctive MDD treatment.","Appointed Cedric O'Gorman, M.D. as CMO and Fabiana Fedeli as independent board director.","Study 302 enrollment expected H1 2024; Study 304 to start mid-2023 with data in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-022428","json":"https://secwatch.observer/filing/0001213900-23-022428.json","markdown":"https://secwatch.observer/filing/0001213900-23-022428.md","text":"https://secwatch.observer/filing/0001213900-23-022428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023022428/0001213900-23-022428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023022428/ea175642-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T18:12:44.179069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ac93e625e9a72d0dab071d835bc97c06a4f6145a","claim":"RELMADA THERAPEUTICS, INC. reported for the year ended December 31, 2022 results: net income -$157.0 million, EPS -$5.30.","evidence_excerpt":"Net loss for the year ended December 31, 2022 and 2021 was $157.0 million and $125.8 million, respectively. The Company had a net loss of $5.30 and $7.16 per share for the year ended December 31, 2022 and 2021, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023022428/0001213900-23-022428-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the year ended December 31, 2022"},{"label":"Net income","value":"-$157.0 million"},{"label":"EPS","value":"-$5.30"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}